Vaxart reports no serious adverse events in oral COVID vaccine trial

July 6, 2026 4:01 PM

Vaxart, Inc. (OTCQX: VXRT) released topline 12-month safety data from the 400-participant sentinel safety cohort of its Phase 2b clinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found